Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

호흡기계 작용 약물의 치료군 중복처방 평가기준 개발Therapeutic Duplication Criteria Development of Respiratory System Drugs

Other Titles
Therapeutic Duplication Criteria Development of Respiratory System Drugs
Authors
최경업신현택김남효손현순이영숙
Issue Date
Apr-2012
Publisher
대한약학회
Keywords
DUR; therapeutic duplication; respiratory drugs; cough suppressants; mucolytics; antihistamines
Citation
약 학 회 지, v.56, no.2, pp 126 - 135
Pages
10
Journal Title
약 학 회 지
Volume
56
Number
2
Start Page
126
End Page
135
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/12243
ISSN
0377-9556
Abstract
Purpose: To develop therapeutic duplication criteria for the drugs used for respiratory diseases. Method: Therapeutic duplication was defined as "more than 2 drug ingredient-usage in which each has the same therapeutic effect and combination therapy does not confer additional therapeutic benefit". Respiratory system drugs approved in Korea were examined for the study. The WHO’s Anatomical Therapeutic Chemical Classification System was used for grouping of the corresponding drug ingredients. The principles and recommendations on combination usage or multiple drug regimens were reviewed by using the clinical practice guidelines, textbooks, product labelings, and clinical articles. Clinical expert group consultation was performed and expert opinions were incorporated into the final criteria. Results: Nine hundred sixty two drug products with Korean Food and Drug Administration classification codes of 141, 149, 222, and 229 were evaluated, of which 87 active ingredients were composed. The drug ingredients were classified into 12 groups (antihistamines, oral nasal decongestants, leukotriene receptor antagonists, inhaled anticholinergics, inhaled corticosteroids, oral β2-agonists, long-acting β2-agonists, short-acting β2-agonists, xanthines, antiallergics, mucolytics and cough suppressants). The use of more than 2 drug ingredients including the same group was therapeutic duplication, and thus combination should be recommended not to be used. Conclusion: Twelve drug groups were identified as therapeutic duplication criteria. Combination therapy within each group should not be used otherwise therapeutic benefits outweigh potential risks.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE